Pfizer Inc. (PFE) Stake Lowered by Federated Investors Inc. PA
Federated Investors Inc. PA cut its stake in Pfizer Inc. (NYSE:PFE) by 3.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,542,728 shares of the biopharmaceutical company’s stock after selling 78,002 shares during the period. Federated Investors Inc. PA’s holdings in Pfizer were worth $82,588,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of Pfizer during the fourth quarter valued at about $384,874,000. State Street Corp boosted its position in shares of Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock valued at $10,419,393,000 after buying an additional 10,838,463 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of Pfizer during the third quarter valued at about $88,268,000. KBC Group NV boosted its position in shares of Pfizer by 63.4% in the third quarter. KBC Group NV now owns 4,444,429 shares of the biopharmaceutical company’s stock valued at $150,533,000 after buying an additional 1,724,137 shares in the last quarter. Finally, Prudential PLC boosted its position in shares of Pfizer by 21.4% in the fourth quarter. Prudential PLC now owns 9,576,618 shares of the biopharmaceutical company’s stock valued at $311,049,000 after buying an additional 1,685,053 shares in the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.
Pfizer Inc. (NYSE:PFE) opened at 34.38 on Tuesday. Pfizer Inc. has a 52-week low of $29.17 and a 52-week high of $37.39. The stock has a market cap of $204.63 billion, a price-to-earnings ratio of 29.31 and a beta of 0.94. The stock has a 50 day moving average price of $33.34 and a 200 day moving average price of $32.84.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The company had revenue of $13.60 billion for the quarter, compared to analyst estimates of $13.64 billion. During the same quarter in the previous year, the firm earned $0.53 EPS. The firm’s revenue was down 3.0% on a year-over-year basis. Analysts expect that Pfizer Inc. will post $2.55 EPS for the current fiscal year.
Your IP Address:
Several research analysts have recently issued reports on PFE shares. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, January 25th. Jefferies Group LLC reiterated a “hold” rating and issued a $30.00 price target on shares of Pfizer in a report on Thursday, January 19th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.83 price target on the stock. in a report on Wednesday, January 18th. Barclays PLC upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and set a $38.00 price target on the stock in a report on Tuesday, November 29th. Finally, Goldman Sachs Group Inc set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, January 18th. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.32.
In related news, insider Rady A. Johnson sold 4,500 shares of the business’s stock in a transaction on Friday, March 10th. The shares were sold at an average price of $34.19, for a total transaction of $153,855.00. Following the transaction, the insider now owns 54,963 shares in the company, valued at approximately $1,879,184.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mikael Dolsten sold 30,970 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $34.51, for a total transaction of $1,068,774.70. Following the transaction, the insider now owns 64,719 shares in the company, valued at approximately $2,233,452.69. The disclosure for this sale can be found here. Insiders have sold a total of 71,470 shares of company stock worth $2,449,150 in the last quarter. 0.07% of the stock is owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.